A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 50
- 主要终点
- Mean Elevated Intraocular Pressure (IOP) During Treatment
研究概览
简要总结
Patient charts will be reviewed to evaluate the incidence of intraocular pressure spikes while on Loteprednol etabonate ophthalmic suspension 0.5%, Loteprednol etabonate (0.5%) and tobramycin (0.3%)
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Any patient who experienced an IOP spike while using Lotemax or Zylet will be included
排除标准
- 未提供
研究组 & 干预措施
1
Loteprednol etabonate ophthalmic suspension 0.5%
干预措施: Loteprednol etabonate ophthalmic suspension 0.5% (Drug)
2
Loteprednol etabonate (0.5%) and tobramycin (0.3%)
干预措施: Loteprednol etabonate (0.5%) and tobramycin (0.3%). (Drug)
结局指标
主要结局
Mean Elevated Intraocular Pressure (IOP) During Treatment
时间窗: 55 days
Mean elevated IOP during treatment. IOP is a measurement of the fluid pressure inside the eye. IOP was recorded any time an elevation of IOP (increase of 5 mmHg or more) occurred while using study treatment. The median duration of treatment at the time of observed IOP elevation was 55 days.
次要结局
未报告次要终点